

Optimal deployment of limited vaccine supplies to combat mpox

Matthew T Berry¹

C Raina MacIntyre²

Deborah Cromer¹

Adam Hacker³

Miles P Davenport¹

David S Khoury^{1*}

¹. Infection Analytics Program, Kirby Institute, UNSW Sydney, Kensington NSW 2052
Australia

². Biosecurity Program, Kirby Institute, UNSW Sydney, Kensington NSW 2052 Australia

³. Coalition for Epidemic Preparedness Innovations, Post box 1030 Hoff, 0218 Oslo,
Norway

*Address for correspondence:

dkhoury@kirby.unsw.edu.au

29 **Abstract:**

30 Mpox outbreaks in Central Africa have been declared a public health emergency of
31 international concern by the World Health Organization. Fortunately, real-world effectiveness
32 studies of the MVA-BN vaccine indicate that it has an effectiveness of 74% after one dose,
33 and 82% after two doses against mpox. However, given the very limited supply of vaccines in
34 Central Africa, there remain questions around the optimal deployment of limited MVA-BN
35 doses. In this study, we consider whether more mpox cases might be averted by following the
36 traditional two-dose vaccine regimen (4 week dosing interval), or by giving a single dose of
37 MVA-BN to as many individuals as possible. We find that the optimal strategy depends on
38 both, (i) the degree to which a subpopulation might be at higher risk of mpox, or severe
39 mpox, infections, and (ii) how long ago the first dose was administered to the most at-risk
40 subpopulation.

41

42

43

44

45 **Introduction**

46 There are concurrent outbreaks of mpox clades I and II globally¹. Of great concern is the
47 current clade I outbreak in central Africa with high case rates, increasing transmission and
48 case-fatality ratio reported at approximately 2% (African continent average), and higher in
49 children^{2,3}. Fortunately, there is considerable evidence that vaccinia-based vaccines are
50 effective at preventing both mpox infection and at reducing the severity of illness⁴⁻⁶. The
51 evidence of vaccine effectiveness (VE) is derived from real-world effectiveness studies of the
52 third generation MVA-BN vaccine in western populations during the clade IIb pandemic of
53 2022-2023⁷⁻¹⁰. A number of older studies in the Democratic Republic of Congo (DRC,
54 formally Zaire) have also shown that vaccination with first generation vaccinia-based
55 vaccines is protective against mpox¹¹⁻¹³. However, third generation vaccines are preferable to
56 early vaccinia-vaccines because of the superior safety and utility in immunosuppressed
57 individuals¹⁴. Despite the urgent need to vaccinate at-risk populations, particularly in the
58 DRC and neighbouring countries, vaccine availability is limited¹⁵. Africa CDC estimate 10
59 million doses are required to control the epidemic¹⁶. Japan has committed 3 million doses of
60 LC16, although to date no supply has reached DRC or neighbouring countries.


61 Approximately 200,000 doses of MVA-BN (Jynneos) arrived in DRC in September 2024.
62 LC16 is a single dose regimen, while MVA-BN is currently recommended as a two-dose
63 regimen (given 4 weeks apart)¹⁷. The DRC has a population of more than 110 million.
64 Therefore, how to optimally deploy a limited stock of vaccines to avert the greatest number
65 of clinical cases, particularly severe cases, is a critical question at present.

66
67 Recently, multiple meta-analyses of real-world effectiveness studies of MVA-BN have
68 analysed the effectiveness of one-dose and two-dose MVA-BN against clade IIb mpox⁴⁻⁶.
69 These have shown a relatively incremental improvement in vaccine effectiveness after two
70 doses compared with a single dose. For example, the World Health Organization (WHO)
71 states that one dose and two doses of MVA-BN provide 76% and 82% effectiveness against
72 mpox, respectively¹⁸. In our own meta-analysis we estimated very similar vaccine
73 effectiveness of 74% after one dose and 82% after two doses. Based on this comparison, we
74 commented that in the case of limited vaccine supply, it would be optimal to deploy a single
75 dose of vaccine to as many individuals as possible rather than administer two doses to half as
76 many individuals⁴. However, this analysis did not include modelling of the waning of vaccine
77 effectiveness with time after one dose vaccination (i.e. the comparison was based on reported
78 vaccine effectiveness from clinical studies, and did not model the predicted decay of vaccine

79 effectiveness over time). Further, the analysis only considered the situation of a population at
80 homogeneous risk of infection, but did not consider the implications of high-risk groups for
81 both infection and for severe outcomes, as is currently observed across age groups in the
82 clade I outbreak in the DRC^{2,19}. Here we consider the question of the optimal deployment of
83 a limited number of MVA-BN doses given the likely waning of vaccine effectiveness, and in
84 a population where there are subgroups at different risk of infection and severe outcomes. In
85 particular, we are interested in the decision, at a particular time point, of whether to use a
86 limited supply of MVA-BN vaccines to deliver a second dose to those who have already
87 received a first dose of MVA-BN or to deploy a first dose of the limited vaccine stock to
88 naïve individuals. This question does not consider the reason individuals may have received a
89 first dose in the past (e.g. either as post-exposure prophylaxis or as primary prevention), or
90 the protection the first vaccine doses have provided up to the time our decision must be made.
91 But rather, we only ask, from the time of our current decision on deployment, what is the
92 relative advantage of deploying a limited stock of these vaccines as second doses to those
93 already partially vaccinated or as first doses to those who have not yet received any vaccine
94 doses?

95
96 It is important to note that, in this study, we rely on data and modelling of MVA-BN
97 effectiveness derived from the clade IIb global outbreaks, but throughout our analysis we
98 discuss these results assuming they are translatable to the contemporaneous clade I outbreaks
99 in Africa. Although it is generally thought that these vaccines will also be effective against
100 clade I mpox (since immunity to orthopoxviruses is often cross-protective¹⁴), confirmatory
101 studies showing that these vaccines are effective against clade I mpox are currently lacking,
102 and are urgently needed. Further, in this analysis we do not explicitly model mpox
103 transmission or consider the impact of different vaccination strategies on transmission or the
104 epidemic trajectory, since there is limited data to inform these outcomes. Instead, we consider
105 the distribution of a limited supply of vaccines where the primary goal is to reduce risk of
106 infection and severe outcomes in particular cohorts.

107
108
109
110



111

112 **Figure 1: Estimating the protection from using MVA-BN in a one versus two-dose**
 113 **schedule.** A) The previously reported vaccine effectiveness of first-generation vaccinia
 114 immunisation, and one and two dose MVA-BN vaccination (against clade IIb virus) from a
 115 systematic review and meta-analysis of the available data⁴. B) The predicted vaccine
 116 effectiveness over time for one dose, two doses spaced 4 weeks apart, and delayed two dose

117 (administered at 2 years). These predictions are from reference ⁴, where a model-based meta-
118 analysis was performed that linked reports of vaccinia-binding antibody titres after MVA-BN
119 vaccination and real-world effectiveness studies, and vaccine effectiveness over time was
120 extrapolated by assuming these binding titres predict vaccine effectiveness (which is not yet
121 confirmed). C) Schematic of potential vaccine allocation options assuming additional vaccine
122 is available 4 weeks after primary vaccination (top) or at some later timepoint (bottom). In
123 each case we compare the outcome of either giving a second dose to those already vaccinated
124 or allocating the additional vaccine as first doses to a naïve population. D) The ratio of cases
125 averted by administering a first dose to naïve individuals compared to a second dose
126 administered at 4 weeks, measured over the first two years after vaccination. The ratio does
127 not vary much over the time interval being considered. E) The ratio of cases averted by
128 giving a one dose regimen rather than a two-dose regimen, estimated using the vaccine
129 effectiveness observed in a meta-analysis of real world effectiveness studies⁴ (left, black) or
130 predicted from a model-based meta-analysis using predictions of waning and different dose
131 spacing⁴. Note that in the case of giving a second dose at 6 and 12 months we make the
132 assumption that peak antibody binding titres and decay in titres will resemble that seen after
133 giving a second dose at 2 years (the only delayed interval for which immunogenicity data was
134 available⁴). This assumption inflates the predicted benefit of the two-dose regimen.
135

136

137

138 **Results**

139 **Comparing one-dose versus two-dose MVA-BN vaccination strategies over two years**

140 In a previous study we estimated that distributing limited doses of MVA-BN as a single dose
141 regimen would avert around 1.8-fold more cases of mpox than deploying the same number of
142 doses as a two-dose regimen⁴. This was based only on the comparative reported effectiveness
143 of the one and two dose regimens (fig. 1A). However, vaccinia-binding antibody titres wane
144 over time, and if antibody responses are predictive of protection, vaccine effectiveness
145 against symptomatic infection may wane in parallel⁴ (fig. 1B). Therefore, in this case, it is
146 important to model the possible effect of this decay on the comparative benefits of a one- vs.
147 two-dose regimen. We consider a scenario where one dose of vaccine has been deployed to
148 some groups of individuals either as primary prevention or post-exposure prophylaxis, and at
149 some later timepoint authorities will have a choice to either administer a second dose to those
150 same individuals already primed, or to administer a first dose of vaccine to naïve individuals
151 (fig. 1C). Without modelling the effects of waning immunity, using only the estimates of
152 vaccine effectiveness from our previous meta-regression of real world effectiveness studies⁴,
153 a one-dose vaccination schedule is predicted to avert 1.80-fold (CI: 1.50-1.92), as we
154 reported previously. In order to account for the impact of waning vaccine effectiveness,
155 assuming a fixed force of infection over time, the ratio of the cases averted with each strategy

156 can be calculated as the ratio of the average vaccine effectiveness over a given time interval,
157 beginning when the vaccines are deployed under one or the other strategy (note that we also
158 consider the more general case of a varying force of infection in the supplementary material).
159 Modelling of the decay of vaccinia-binding antibody titres and protection suggests that the
160 benefit of administering a first dose to as many people as possible is relatively constant over
161 the first two years after vaccination (fig. 1D). In the subsequent analysis we focus on a time
162 interval of 2 years after deployment, by which time, if an outbreak continues to intensify,
163 vaccine manufacturing and supply are likely to have increased.


164

165 The analysis above considers the scenario where sufficient vaccine is available to deliver a
166 second dose 4 weeks after the first. However, if vaccine becomes available later after the first
167 dose, does this change the relative benefit of a one-dose vs. a two-dose strategy? Studies have
168 shown that delaying the second dose until 2 years after the first dose leads to a higher peak
169 titre and slower decay of antibody titres post-vaccination²⁰. Thus, in addition to declining
170 protection from the initial one-dose vaccination over time, the relative benefit of
171 administering a delayed second dose is expected to increase over time. To model this
172 scenario, we take the same function of waning one-dose immunity as above (fig. 1B). Of
173 note, we only have data on the impact of increasing the spacing of two doses from 1 month to
174 2 years (fig. 1B), and do not have detailed data on the effects of different dose-spacing
175 intervals on antibody titres. However, we make the assumption that delaying the second dose
176 to six months or more induces a similar peak immune response to that achieved with a second
177 dose at 2 years (fig. 1B), which is an assumption that is expected to overestimate the
178 protection from the two-dose regimen when the second dose is administered at 6 or 12
179 months. After accounting for waning immunity and higher predicted protection with a
180 delayed second dose, administering a first dose to as many individuals as possible is still
181 predicted to maximise the cases averted from mpox compared to a two-dose strategy (fig.
182 1E). This is observed whether additional vaccine becomes available, 4 weeks, 6 months or 12
183 months after priming and despite our use of a conservative approach to estimating the effect
184 of a delayed second dose (that will favour a two-dose regimen). We estimate there is still a
185 1.59-fold (CI: 1.24-1.84) advantage of administering first doses to naïve individuals
186 compared to a strategy of administering a second dose to those already vaccinated individuals
187 at 12 months.

188

189

190



191

192 **Figure 2: Predicting the effects of distributing vaccine doses between risk groups.** A) Schematic of allocation scenario. We assume that a first dose of vaccine has been
 193 administered to a high-risk group, and at some later time more vaccine becomes available.
 194 These vaccines could either be allocated as second doses to the high-risk group, or
 195 administered as a first dose to a lower-risk group. (B) Depending on the ratio of risk in the
 196 high-risk and lower-risk groups (x-axis), then the predicted ratio of cases averted by the one-
 197 dose compared to the two-dose strategy (y-axis) will vary. This will also vary with the
 198 spacing between doses (colours), with longer delays since first dose in the high-risk group
 199 favouring the strategy of a second dose to the high-risk group. The horizontal dashed line
 200 shows a ratio of one (i.e. where we flip from favouring a one-dose approach to favouring a
 201 two-dose approach). Results are shown for prevention of any clinical mpox infection. (C) The
 202 risk threshold (y-axis) is the risk ratio at which the optimal strategy changes from favouring a
 203 one-dose to favouring a two-dose regimen. The risk threshold predicted from the vaccine
 204 effectiveness reported in clinical studies is on the left (black), and the threshold estimated
 205 from model-based meta-analysis (including vaccine waning for vaccine administered at 4, 26,
 206 or 52 weeks) is shown on the right.
 207
 208

209

210


210 Considering heterogeneous risk groups

211 In the analysis above we see that in the case of a population at-risk and limited vaccine doses,
 212 giving as many people as possible a first dose of MVA-BN would avert more cases than

213 giving half as many people two doses of MVA-BN. However, this only considers a
214 population with homogenous risk of infection and does not consider the possibility of some
215 subgroups being at greater risk of infection and / or of severe outcomes than others. The latest
216 data from the DRC highlights that risk of both infection and the case-fatality ratios of clade I
217 are much higher in young children than older children and adults². Therefore, it is important
218 to consider when it might be optimal to deploy a second dose of MVA-BN to those most at
219 risk, rather than to give a first dose to people at a lower risk for primary prevention of mpox.
220 We consider a scenario of two identifiable risk groups, one with high risk, and one with lower
221 risk of mpox infection. Initially, it is favourable to target the high-risk individuals with a first
222 dose. However, when the majority of the high-risk individuals have already received a first
223 dose of MVA-BN, we ask whether it is optimal to administer a second dose to the high-risk
224 group or deliver a first dose to those in the lower risk group (fig. 2A). Specifically, we
225 consider how many times higher the risk would need to be in a population before it becomes
226 optimal to target high-risk individuals with a second dose instead of targeting lower risk
227 individuals with a first dose (which we refer to as a ‘risk-threshold’ above which the two-
228 dose regimen is preferred).

229 Using only the vaccine effectiveness from our meta-analysis of real-world data, we estimate
230 that unless the high-risk group is at least 9.0-fold (95% CI: 3.0-25) more likely to be infected
231 than the lower risk group, it is preferable to administer any additional vaccines as first doses
232 to the lower risk group. If we take into account waning immunity and protection over the first
233 two years after deployment, we see a similar risk-threshold for when we should favour a two-
234 dose regimen (fig. 2B). If additional vaccines only become available at 6 months or 12
235 months after the first dose, the risk-threshold is reduced to 3.9-fold (CI: 1.6-11) because of
236 waning immunity after the first dose and a higher response after a delayed second dose (fig.
237 2C) (using the assumption that a second dose at 6 months or 12 months gives the same peak
238 protection as it would at 2 years, which is a conservative assumption, as it tends to decrease
239 the risk-threshold). Together this suggests that given the relative effectiveness of one vs two
240 doses, unless a subgroup is known to have at least a 3.9-fold (CI:1.6-11) higher risk of
241 infection, it is optimal to continue to administer a first dose to lower risk populations before
242 giving second doses to the high-risk population.

243



244

245 **Figure 3: Comparison of vaccine strategies against preventing severe mpox cases.** A)

246 The ratio of severe cases averted by giving a one-dose regimen compared to a two-dose

247 regimen - based on the vaccine effectiveness observed in the clinical studies (left, black) or

248 predicted (when the doses are spaced at 4, 26, or 52 weeks) from a model-based meta-

249 analysis (right). B) The risk threshold (the ratio of risk in the high-risk group compared to the

250 low risk) that favours the switch from the one-dose to the two-dose regimen for severe mpox.

251 The risk threshold predicted from the vaccine effectiveness reported in clinical studies (left,

252 black), and the model-based meta-analysis for vaccine administered at 4, 26, or 52 weeks

253 (right). C) The ratio of severe cases averted when comparing vaccination strategies between

254 administering second doses to a high-risk group or first dose to a lower risk group with

255 different dosing intervals (colours). The dashed horizontal line represents the risk threshold

256 where a switch occurs from favouring a one-dose to favouring a two-dose regimen.

257

258 Averting severe outcomes

259 In the scenario above we only considered the optimal strategy to avoid the most mpox cases

260 of any severity (mild, moderate or severe). However, case-fatality rates in children under 5

261 years of age have been reported at 3.2-times higher than in adults and children older than 15

262 years². These observations are based on very limited epidemiological data and may suffer

263 from a range of confounding²¹. However, if the goal of vaccination were to reduce severe

264 mpox (rather than any clinical mpox infection), this raises the question of whether we should

265 favour deploying limited vaccine stocks as a one- or two-dose regimen, and under what

266 conditions we should target high-risk groups for two-dose vaccination?

267 Unfortunately, there is very limited data available on vaccine effectiveness in preventing

268 severe mpox infection (and none for clade I infection). However, a comprehensive meta-

269 analysis of studies of individuals with breakthrough mpox clade IIb infection suggested a

270 66.6% (95% CI: 55-78%) vaccine effectiveness against progression from mild infection to

271 hospitalisation⁵, and there appears similar vaccine effectiveness in preventing progression to

272 severe mpox after either one or two doses of MVA-BN. Assuming that one dose MVA-BN

273 has 74% effectiveness at preventing infection and two doses of MVA-BN has 82%

274 effectiveness, and assuming both provide 66% protection against progressing to severe
275 outcomes, we can estimate from this that the vaccine effectiveness at preventing severe
276 infections that lead to hospitalisation is around 91% for a one-dose, and 94% for a two-dose
277 regimen.

278 Using only these estimates of vaccine effectiveness from the meta-analysis of real-world
279 studies, we can predict that, for a homogenous population, administering additional vaccines
280 as a first dose to naïve individuals will prevent 1.94-fold (CI: 1.86-1.98) more cases of severe
281 mpox (fig. 3A). We observe similar results when accounting for waning of protection (fig.
282 3A). Thus, as was the case when looking at averting mpox cases of any severity (fig. 1E), the
283 one-dose strategy is predicted to be optimal if the goal of vaccination is to maximise
284 protection from severe mpox infection.

285 As we did above for mpox cases of any severity, we can also analyse the situation where
286 there are identifiable subgroups that are at higher risk of severe infection. Again, here we
287 consider a scenario where the high-risk group has already received one dose of vaccine, and
288 we have the choice of deploying additional vaccine doses as second doses to the high-risk
289 group, or as first doses to a low-risk group. Using only the data from the real-world studies of
290 vaccine effectiveness, we predict that unless the high-risk group were at greater than 33-fold
291 (CI:14-93) higher risk of severe infection than the low-risk group, we should favour
292 administering one dose of the vaccine to as many people as possible rather than giving a
293 second dose to the high-risk population (fig. 3B). The result is similar when accounting for
294 the predicted waning of vaccine effectiveness with time (fig. 3C). That is, applying our
295 predictions of waning vaccine effectiveness⁴, we predict that early after vaccination, giving a
296 first dose to more people would be favoured unless the high-risk group had at least 37-fold
297 (CI:17-107) times higher risk of severe infection compared to the low-risk group (fig. 3B).
298 Finally, if a second dose is delayed to 6 months or 12 months after the first dose (again using
299 the conservative assumption that a second dose at 6 months or 12 months gives the same peak
300 protection as it would at 2 years), the single dose strategy will remain favoured unless the
301 high-risk group has more than a 15-fold (CI: 7-43) higher risk of severe infection compared
302 to the lower risk group (fig. 3B).

303

304

305

306 Discussion

307 In the context of adequate vaccine availability, delivering the recommended two dose MVA-
308 BN schedule to as many people as possible can achieve rapid population protection. Here we
309 do not advocate for changes to the recommended vaccine schedule generally, or delaying the
310 second dose of MVA-BN as a standard approach. However, in the current mpox public health
311 emergency there are limited vaccine stocks in the countries most in need, which raises a
312 number of questions about the optimal deployment of limited vaccine resources. Here we find
313 that in a population of homogenous risk, deploying limited vaccine stocks as single doses to
314 as many people as possible is always favoured. In the presence of high-risk populations,
315 deploying vaccine as single doses is favoured unless the high-risk population is at greater
316 than 9 times higher risk of clinical mpox infection compared to the low-risk population. For
317 sub-populations at high risk for severe disease, administering one dose to as many people as
318 possible is still favoured unless the high-risk group is at greater than 33-fold higher risk of
319 severe mpox infection (Figure 2E). However, if additional doses of vaccine only become
320 available 6 months to a year after the first dose, the estimated benefit of the one-dose regimen
321 is slightly lower. Waning immunity from the earlier first dose of vaccine and the higher
322 (vaccinia-binding) antibody titres achieved after a delayed second dose (and the assumed
323 greater protection this may yield), suggests that the risk threshold favouring a second dose to
324 high-risk subpopulations declines to be only a 3.9-fold higher risk of clinical mpox, or 15-
325 fold higher risk of severe outcomes. These predicted thresholds have wide credibility
326 intervals and rely on a number of assumptions discussed below.

327

328 It is important to note that although we discuss in this paper the ratio of cases averted under
329 the different vaccine deployment strategies, this quantity was only possible to calculate here
330 under the assumption of a constant force of infection with time. Given expanding case
331 numbers during an outbreak and the potential impact of public health interventions, risk of
332 infection will likely vary over time. Fortunately, in the supplementary material we show that
333 the same results hold when considering the more complex case of a time varying force of
334 infection (supplementary material). In fact, we show when the force of infection is time
335 variable, a similar quantity to that which we calculate in the main analysis (the ratio of
336 vaccine effectiveness between the two strategies, equation 5) is similarly indicative of the
337 optimal strategy.

338

339 Experience with smallpox and Ebola showed that using contact tracing and ring vaccination
340 was a dose-sparing and efficient strategy, albeit with lower vaccine effectiveness due to being
341 administered in a post-exposure prophylaxis setting²². Such strategies have the potential to
342 further increase the number of cases averted by controlling the epidemic sooner. However, in
343 our modelling here we have not considered these complementary vaccine deployment
344 strategies. This is largely because there are very limited data available on the risks of
345 infection among contacts, and current estimates for vaccine effectiveness when used as post-
346 exposure prophylaxis have high uncertainty, but may be quite low⁵.

347

348

349 We consider two different methods in our analysis to compare the effectiveness of one- and
350 two-dose regimens. Each of these approaches come with a number of caveats and limitations.
351 In the first approach, we use only the estimates of vaccine effectiveness from meta-analyses
352 of real-world effectiveness studies to compare the ratio of cases averted under the different
353 vaccination strategies (Figs 1E,2C). A strength of this approach is that it does not assume any
354 relationship between antibody titres and protection, and does not consider waning immunity
355 (other than any waning that may have been present in the clinical studies themselves).
356 However, as a result this approach implicitly assumes vaccine effectiveness does not wane.
357 The second approach involves analysis of the relationship between vaccinia-binding antibody
358 titres and vaccine protection, along with analysis of antibody boosting and waning antibody
359 levels to predict vaccine effectiveness at different times⁴. This is of course significantly less
360 direct than the approach described above and relies on the assumption that vaccinia-binding
361 antibody levels are predictive of vaccine effectiveness against mpox over time, and that
362 antibody titres and immunity will wane in a similar way in the populations at risk of mpox.
363 The limitations of this modelling approach are outlined in detail in the original study⁴.
364 Further, rather than relying on predictions of the vaccine effectiveness over time from the
365 decay in antibody responses, real world effectiveness data out to 1 to 2 years post MVA-BN
366 vaccination (with either one or two doses) would be very informative. Fortunately, this data is
367 likely available, or soon to be available, in many settings given vaccination during the
368 2022/2023 clade IIb outbreaks and ongoing clade IIb transmission globally. Further work is
369 clearly needed to validate antibody levels as a predictor of vaccine effectiveness against
370 clinical mpox, against severe mpox, and to investigate antibodies and protection over time in
371 the context of clade I virus.

372

373 Both our analysis approaches assume that vaccine supply is low compared to the total
374 susceptible population, such that the deployment strategies do not impact the force of
375 infection. Further, neither approach considers time to epidemic control, where the delay
376 between dose 1 and dose 2 would be influential. Also, both of these methods rely on the
377 results of our meta-analysis of real-world effectiveness studies⁴. There are now three
378 systematic reviews of MVA-BN vaccine effectiveness⁴⁻⁶, which give similar estimates of one
379 and two-dose vaccine effectiveness in the context of clade IIb infection. However, the
380 underlying real-world studies included in these meta-analyses each have considerable
381 limitations^{4,5}. Further, there is very limited data on vaccine effectiveness against severe mpox
382 infection, and we base our analysis of severe protection on a single meta-analysis of vaccine
383 effectiveness against progression from symptomatic to severe clade IIb infection⁵. Clearly
384 further studies of vaccine effectiveness against clade Ia and Ib and against severe mpox
385 would be valuable to provide data directly relevant to these clades.

386

387 Our analysis of vaccine effectiveness against severe mpox relies on the assumption that the
388 vaccine effectiveness estimates we used from real-world effectiveness studies will also apply
389 to the at-risk population. However, vaccine effectiveness may differ for groups at risk of
390 severe mpox such as children, people with HIV, or immunocompromised individuals²³.
391 Differences in one- and two-dose effectiveness in such risk groups would change the relative
392 advantage of a one-dose regimen. Recent reports of vaccine effectiveness in people with HIV
393 suggest that this may be similar to the general population²⁴. However further studies are
394 clearly needed to understand vaccine immunogenicity and effectiveness across different at-
395 risk populations in order to guide rational vaccine deployment.

396

397 Notwithstanding the many limitations of the available data, this analysis suggests that where
398 limited stocks of MVA-BN vaccine are available, deploying them as a single dose regimen to
399 as many people as possible will usually be the most effective strategy to reduce the incidence
400 of mpox. However, providing second doses to high-risk populations may be favoured if the
401 risk-ratio to the general population is sufficiently high. Delaying second doses in the context
402 of limited vaccine supply is not a novel approach. During the COVID-19 pandemic limited
403 supply of the AstraZeneca vaccine in the UK led to increased dosing intervals²⁵, and this was
404 accompanied by higher vaccine efficacy than reported with the original (4 week) dosing
405 schedule²⁶. These conclusions do not advocate for a change in the recommended vaccine
406 schedule for MVA-BN, or for health authorities to ignore this schedule. Vaccine should be

407 deployed with the intention of giving a second dose at four weeks or as soon as possible.
408 However, limited vaccine availability may at times dictate that allocating limited vaccine
409 supplies as a second dose to those already vaccinated is not an efficient strategy to maximise
410 population protection.
411
412
413

414 **Methods**

415 **Modelling the averted cases**

416 To compare different vaccine strategies, we calculated the ratio of cases averted between two
417 alternative deployment strategies. Using the estimates for vaccine effectiveness of one- and
418 two-dose regimens reported from the meta-analysis of real-world effectiveness studies, and
419 assuming that effectiveness does not change with time, we previously calculated the ratio of
420 cases averted (RCA) by using the one-dose regimen compared to the two-dose⁴ is given by,

$$423 \quad RCA = \frac{2VE_1}{VE_2}. \quad (1)$$

421 where, VE_1 and VE_2 are the vaccine effectiveness conferred by one and two doses of MVA-
422 BN, respectively.

424 However, the above approach does not take into account the potential impact of waning
425 immunity over time. We can therefore extend this analysis using our modelled estimates of
426 immune waning and the impact of administering second doses at different times⁴. To model
427 this, we considered a constant force of infection (infection rate), r , within the population of
428 concern. We analyse a scenario in which a proportion of individuals has already received the
429 first dose of vaccine, and at some later time more vaccine doses become available that can
430 either be deployed as second doses to those already vaccinated or as first doses to naïve
431 individuals. We assume the number of additional vaccines available (for which a deployment
432 decision is required), d , is much less than the vulnerable population, N , and that at least d
433 people have received a first dose s days earlier (see supplementary methods). By assuming
434 the number of vaccines is small, we assume that the vaccine deployment decision does not
435 affect the force of infection.

436
437 The cases averted, CA , by a given vaccine strategy compared to a naïve population is then
438 given by,

$$439 \quad CA = \text{Vaccine Effectiveness} \times \text{Number of people vaccinated} \times \text{Force of infection}.$$

440 In the case where additional vaccine is deployed in a one-dose regimen to naïve individuals,
441 then the overall protection in the population includes the protection of already vaccinated
442 individuals, plus the protection from the vaccination of naïve subjects. It follows that the
443 expected number of cases averted if the d doses are administered to naïve individuals who
444 have not been previously vaccinated is,

$$445 \quad CA_1(t) = \int_0^t VE_1(x+s)dx \times d \times r + \int_0^t VE_1(x)dx \times d \times r, \quad (2)$$

446 where, $CA_1(t)$, is the cumulative number of cases averted by time t (in days), and
447 $\int_0^t VE_1(x)dx$ is the cumulative vaccine effectiveness of one dose of MVA-BN over time, t ,
448 and r is the infection rate (i.e. force of infection, see supplement for full derivation). Note
449 that the term $VE_1(x + s)$ captures that those who were vaccinated with one dose already
450 received this dose s days before the current batch of vaccines were deployed, and thus the
451 effectiveness from this dose will have waned for longer than those who have just received
452 their first dose.

453 Similarly, if these doses are administered as second doses, the number of cases averted by
454 time t is given by,

$$455 \quad CA_2(t) = \int_0^t VE_{2,s}(x)dx \times d \times r. \quad (3)$$

456 where, $CA_2(t)$, is the cumulative number of cases averted by time (t) by the two-dose
457 strategy, $\int_0^t VE_{2,s}(x)dx$ is the cumulative vaccine effectiveness of two doses of MVA-BN
458 over time, t , and s is the interval between the two doses administered.

459 For simplicity we assume that the maximum effectiveness is obtained 14 days after
460 vaccination for both one and two doses.

461 Thus, we can define the ratio of cases averted by time t as,

$$462 \quad RCA(t) = \frac{CA_1(t)}{CA_2(t)} = \frac{\int_0^t VE_1(x)dx + \int_0^t VE_1(x + s)dx}{\int_0^t VE_{2,s}(x)dx}. \quad (4)$$

463 This ratio of cases averted by time t is equivalent to the ratio of the average vaccine
464 effectiveness in the population. To calculate the RCA , we require estimates of vaccine
465 effectiveness and the waning of immunity. For this we use our estimated vaccine
466 effectiveness, and waning of vaccine effectiveness with time, from our previously published
467 model-based meta-analysis of real world-effectiveness data⁴. In particular, we use the
468 posterior samples of our parameters from our meta-analysis to calculate the ratio in equation
469 4, and the credible intervals around these ratios. The accuracy for the waning of vaccine
470 effectiveness depends on a number of assumptions from our modelling of the relationship
471 between antibody titres and vaccine effectiveness estimates⁴.

472

473 Note that we have employed a model of the ratio of cases averted in this work for ease of
474 interpretation. Importantly, the ratio described in equation 4 only represents the ratio of cases
475 averted under the simplifying assumption of a uniform force of infection over time
476 (supplementary material). However, it should be noted that even in the case where the force

477 of infection is not constant, a very similar ratio, which we call the ratio of vaccine
478 effectiveness in the vaccinatable population (RVE),

$$479 \quad RVE(t) = \frac{VE_1(t+s) + VE_1(t)}{VE_{2,s}(t)}, \quad (5)$$

480 is descriptive of the optimal strategy. As we show in the supplementary material for a time
481 varying force of infection, if this ratio is greater than 1 at all time points, the one dose
482 strategy will be optimal (see derivation in the supplementary methods).

483

484 **Incorporating groups with different risk of infection or severe disease**

485 We can further extend this model to consider vaccinating two subpopulations with different
486 risks (different force of infection). In this scenario we consider a high-risk group in which
487 everyone has received a first dose of the vaccine. We then consider a scenario where
488 additional vaccine becomes available and we must decide whether to deploy them as second
489 doses for the already vaccinated high-risk population, or as first doses to a lower-risk
490 population. We can estimate the ‘risk threshold’, which is how much higher the risk of
491 infection must be in the high risk population before targeting the high-risk group with a
492 second dose is favoured. Using only the real-world effectiveness data our meta-analysis⁴, and
493 assuming no waning of immunity, we can estimate that this ratio is,

$$494 \quad RCA = \frac{r_l VE_1 + r_h VE_1}{r_h VE_2} \quad (6)$$

495 where, r_h and r_l are the rate of infection in the high and low risk groups, respectively. We
496 define the risk threshold, r_c , to be the ratio such that when $r_h/r_l > r_c$, then more cases are
497 averted by administering second doses to the high-risk group. This risk threshold occurs
498 when $RCA = 1$. Thus, more cases will be averted by a one dose strategy, except when

$$499 \quad \frac{r_h}{r_l} > \frac{VE_1}{VE_2 - VE_1} = r_c. \quad (7)$$

500 We can also extend this to incorporate the effects of waning immunity and delayed
501 vaccination. In this case, the cases averted by administering a single dose is given by,

$$502 \quad CA_1(t) = \int_0^t VE_1(x) dx \times n \times r_l + \int_0^t VE_1(x+s) dx \times n \times r_h, \quad (8)$$

503 and the cases averted in the two-dose strategy is given by,

$$504 \quad CA_2(t) = \int_0^t VE_{2,s}(x) dx \times n \times r_h. \quad (9)$$

505 Thus, we can calculate the ratio of cases as,

506
$$RCA(t) = \frac{\left(\int_0^t VE_1(x) dx \times 1/(r_h/r_l) \right) + \int_0^t VE_1(x+s) dx}{\int_0^t VE_{2,s}(x) dx}. \quad (10)$$

507 This relationship depends on the infection risk ratio between high risk and lower risk
508 individuals (r_h/r_l). If the two populations have equal risk ($r_h/r_l = 1$), then we obtain
509 equation 4. Using equation 10, it follows that the risk threshold is given by,

510
$$r_c = \frac{\int_0^t VE_1(x) dx}{\int_0^t VE_{2,s}(x) dx - \int_0^t VE_1(x+s) dx}. \quad (11)$$

511 This quantity can be calculated across any time period and in our analysis, and we use a
512 period of two years.

513

514 **Conflicts of Interest**

515 CRM is a member of the WHO SAGE advisory group on smallpox and mpox and was a
516 member of the advisory board for Bavarian Nordic in 2022. DSK has collaborated with
517 employees from Merck KGaG, Merck Co., GSK and Zydus Cadila to provide data analysis
518 relating to therapeutic products being developed for treatment of malaria. The authors have
519 no other conflicts of interest to declare.

520

521 **Funding declaration**

522 This work is supported by National Health and Medical Research Council of Australia
523 Investigator Grants (GNT2016907 to CRM, GNT1173528 to DC, GNT1173027 to MPD).
524 DSK is supported by a University of New South Wales Scientia Fellowship.

525

526 **Ethical approval**

527 The analysis and modelling of publicly available de-identified clinical trial data was approved
528 under the UNSW Sydney Human Research Ethics Committee (approval HC200242).

529

530

531

532 References

- 533 1. Rivers, C., Watson, C. & Phelan, A.L. The Resurgence of Mpox in Africa. *JAMA* **332**,
534 1045-1046 (2024).
- 535 2. WHO. Disease Outbreak News: Mpox - Democratic Republic of the Congo. **14 June**
536 **2024**, <https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON2522>
537 (Accessed: 14 Oct 2024).
- 538 3. Africa CDC. Africa CDC Epidemic Intelligence Weekly Report, October 2024. **1 Oct**
539 **2024**, [https://africacdc.org/download/africa-cdc-weekly-event-based-surveillance-](https://africacdc.org/download/africa-cdc-weekly-event-based-surveillance-report-october-2024/)
540 [report-october-2024/](https://africacdc.org/download/africa-cdc-weekly-event-based-surveillance-report-october-2024/) (Accessed: 14 Oct 2024).
- 541 4. Berry, M.T., *et al.* Predicting vaccine effectiveness for mpox. *Nat Commun* **15**, 3856
542 (2024).
- 543 5. Pischel, L., *et al.* Vaccine effectiveness of 3rd generation mpox vaccines against mpox
544 and disease severity: A systematic review and meta-analysis. *Vaccine* **42**, 126053
545 (2024).
- 546 6. Taha, A.M., *et al.* Effectiveness of a single dose of JYNNEOS vaccine in real world:
547 A systematic review and meta-analysis. *Health Science Reports* **7**, e70069 (2024).
- 548 7. Bertran, M., *et al.* Effectiveness of one dose of MVA-BN smallpox vaccine against
549 mpox in England using the case-coverage method: an observational study. *Lancet*
550 *Infect Dis* **23**, 828-835 (2023).
- 551 8. Dalton, A.F., *et al.* Estimated Effectiveness of JYNNEOS Vaccine in Preventing
552 Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–
553 March 31, 2023. *MMWR. Morbidity and Mortality Weekly Report* **72**, 553-558 (2023).
- 554 9. Deputy, N.P., *et al.* Vaccine Effectiveness of JYNNEOS against Mpox Disease in the
555 United States. *N Engl J Med* **388**, 2434-2443 (2023).
- 556 10. Payne, A.B., *et al.* Reduced Risk for Mpox After Receipt of 1 or 2 Doses of
557 JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons—43 US
558 Jurisdictions, July 31–October 1, 2022. *Mmwr-Morbid Mortal W* **71**, 1560-1564
559 (2022).
- 560 11. Breman, J.G., *et al.* Human monkeypox, 1970-79. *Bull World Health Organ* **58**, 165-
561 182 (1980).
- 562 12. Fine, P.E., Jezek, Z., Grab, B. & Dixon, H. The transmission potential of monkeypox
563 virus in human populations. *Int J Epidemiol* **17**, 643-650 (1988).
- 564 13. Jezek, Z., *et al.* Human monkeypox: a study of 2,510 contacts of 214 patients. *J Infect*
565 *Dis* **154**, 551-555 (1986).
- 566 14. WHO. Smallpox and mpox (orthopoxviruses): WHO position paper. **23 Aug 2024**,
567 <https://www.who.int/publications/i/item/who-wer-9934-9429-9456> (Accessed: 16 Oct
568 2024).
- 569 15. Adepoju, P. African mpox surges show lack of vaccine access. *The Lancet* **404**, 18
570 (2024).
- 571 16. Ndembu, N. & Abdool Karim, S.S. Africa aims to avert an mpox pandemic. *Science*
572 **386**, 7-7 (2024).
- 573 17. FDA. Smallpox and Monkeypox Vaccine, Live, Non-Replicating (JYNNEOS):
574 Package Insert. **31 May 2024**,
575 <https://www.fda.gov/media/131078/download?attachment> (Accessed: 22 Oct 2024).
- 576 18. WHO. WHO prequalifies the first vaccine against mpox. **13 Sept 2024**,
577 [https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-](https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox)
578 [against-mpox](https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox) (Accessed: 24 Oct 2024).
- 579 19. Gostin, L.O., Jha, A.K. & Finch, A. The Mpox Global Health Emergency — A Time
580 for Solidarity and Equity. *New England Journal of Medicine* **391**, 1265-1267 (2024).

- 581 20. Ilchmann, H., *et al.* One- and Two-Dose Vaccinations With Modified Vaccinia
582 Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to
583 Replicating Smallpox Vaccines. *J Infect Dis* **227**, 1203-1213 (2023).
- 584 21. Hoffmann, C. Mpox-is there a more dangerous new clade? *Lancet Infect Dis* (2024).
- 585 22. Kucharski, A.J., *et al.* Effectiveness of Ring Vaccination as Control Strategy for Ebola
586 Virus Disease. *Emerg Infect Dis* **22**, 105-108 (2016).
- 587 23. Yinka-Ogunleye, A., *et al.* Mpox (monkeypox) risk and mortality associated with HIV
588 infection: a national case-control study in Nigeria. *BMJ Glob Health* **8**(2023).
- 589 24. Montaña, M., *et al.* Mpox in People With Human Immunodeficiency Virus: Predictors
590 of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort. *Clinical*
591 *Infectious Diseases* (2024).
- 592 25. Roozen, G.V.T., Roukens, A.H.E. & Roestenberg, M. COVID-19 vaccine dose
593 sparing: strategies to improve vaccine equity and pandemic preparedness. *Lancet*
594 *Glob Health* **10**, e570-e573 (2022).
- 595 26. Voysey, M., *et al.* Single-dose administration and the influence of the timing of the
596 booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222)
597 vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881-891 (2021).
- 598